The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer

Prostate

Volumn 67, Issue 9, 2007, Pages 999-1009

  Yonou, Hiroyuki ^a   Ochiai, Atsushi ^b   Ashimine, Satoshi ^b   Maeda, Hiroyuki ^b   Horiguchi, Yutaka ^a   Yoshioka, Kunihiko ^a   Ogawa, Yoshihide ^c   Hatano, Tadashi ^a   Tachibana, Masaaki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Adult human bone; Bisphosphonate; Osteoblastic bone tumor; Osteoclast; Prostate cancer

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; MINODRONIC ACID;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BONE TUMOR; CANCER GROWTH; CANCER PAIN; CELL PROLIFERATION; CELL STRAIN LNCAP; HUMAN; HUMAN CELL; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; STAINING;

ANIMALS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OSTEOBLASTS; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 34249651738     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20592     Document Type: Article

References (37)

1. Linehan WM, Long JP, Steeg PS, Gnarra JR. Metastatic models and molecular genetics of prostate cancer. J Natl Cancer Inst 1992;84:914-915.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-1594.
3. Papapoulos SE, Hanidy NA, van der Pluijm G. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer 2000;88:3047-3053.
4. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
5. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983;51:918-924.
6. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL, Kanis JA. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985;57:721-723.
7. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA. Biochemical and, histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41-49.
8. Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991;68:74-80.
9. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today 2002;38:91-102.
10. Yonou H, Ochiai A, Goya M, Kanomata N, Hokama S, Morozumi M, Sugaya K, Hatano T, Ogawa Y. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 2004;58: 406-413.
11. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000;82:858-864.
12. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-34.
13. Yano S, Zhang H, Hanibuchi M, Miki T, Goto H, Uehara H, Sone S. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clin Cancer Res 2003;9:5380-5385.
14. Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A. Establishment of a novel species-and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001;61:2177-2182.
15. Horoszewicz JS. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
16. Kyoizumi S, Baum CM, Kaneshima H, McCune JM, Yee EJ, Namikawa R. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood 1992;79:1704-1711.
17. Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A. Osteoprotegerin/ osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003;63:2096-2102.
18. Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, Matsumura T. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 1998;77:279-285.
19. Nishida S, Kikuichi S, Haga H, Yoshioka S, Tsubaki M, Fujii K, Irimajiri K. Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines. Biol Pharm Bull 2003;26:96-100.
20. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
21. Cole AA, Walters LM. Tartrate-resistant acid phosphatase in bone cartilage following decalcification and cold-embedding in plastic. J Histochem Cytochem 1987;35:203-206.
22. Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type 1 procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 2001; 87:348-351.
23. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991;9:509-524.
24. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-1244.
25. Sun YC, Geldof AA, Newling DW, Rao BR. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J Urol 1992;148:1270-1273.
26. Nemoto R, Sato S, Nishijima Y, Miyakawa I, Koiso K, Harada M. Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice. J Urol 1990;144:770-774.
27. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005;65:8818-8825.
28. Sasaki A, Williams PJ, Mundy GR, Yoneda T. Osteolysis and tumor growth are enhanced in sites of increased bone turnover in vivo. J Bone Miner Res 1994;9:S294.
29. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986;261:12665-12674.
30. Pfeilschifter J, Mundy GR. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987;84:2024-2028.
31. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-573.
32. Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop 1995;312:34-44.
33. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890-3894.
34. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954.
35. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306.
36. Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996;16:116-131.
37. Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on cancer. Calcif Tissue Int 2003;73:315-318.